000 03424nam a22004095i 4500
999 _c9772
_d9772
001 9772
003 DE-He213
005 20210518040410.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 171031s2018 gw | s |||| 0|eng d
020 _a9783319618722
024 7 _a10.1007/978-3-319-61872-2
_2doi
040 _aES-MaUEC
_bspa
_dES-VaUE
050 4 _aRC280
_b.B6 2018 EB
245 1 0 _aPersonalized Therapy for Multiple Myeloma
_cedited by Saad Z. Usmani, Ajay K. Nooka.
264 1 _aCham
_bSpringer International Publishing :
_bImprint: Springer
_c2018.
300 _a1 recurso en línea (IX, 178 páginas 5 ilustraciones, 3 ilustraciones a color)
336 _2rdacontent
_aTexto (visual)
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
490 0 _aMedicine (Springer-11650)
505 0 _aRisk stratification in newly diagnosed smoldering multiple myeloma -- Risk stratification in newly diagnosed transplant eligible multiple myeloma -- Risk stratification in newly diagnosed transplant ineligible multiple myeloma -- Treatment of translocation 4;14 and deletion 17 p MM -- Treatment of patients in first/second relapse -- Treatment of patients in third relapse and beyond including double refractory disease -- Treatment of primary and secondary plasma cell leukemia -- Practical considerations for bone health in multiple myeloma -- Personalizing MM treatment: gaps in knowledge that we need to overcome.
520 3 _aThis book provides the clinician with concise, practical guidance on risk stratification and therapeutic decision making in patients with multiple myeloma. In addition, the available clinical trial and research data are summarized into meaningful reviews and evidence-based recommendations for treatment are presented. The coverage encompasses all phases and forms of disease, including high-risk myeloma. Over recent decades, greater understanding of the biology of myeloma has fostered the development of new, more effective drugs, leading to remarkable improvements in survival. To continue this momentum, several recent prospective trials have aimed to identify further potential therapeutic targets or to evaluate various combinations of anti-myeloma agents. The increasing abundance of management options makes treatment decision making in different phases of disease. This book will offer the clinician valuable assistance in the choice and sequencing of therapies, highlighting the need for a personalized approach that reflects the growing recognition that myeloma is not one uniform disease.
650 7 _aOncología
_9139207
_2embne
650 7 _aMieloma múltiple
_9160182
_2embne
700 1 _aUsmani, Saad Z.
_eeditor literario
700 1 _aNooka, Ajay K.
_eeditor literario
_0http://id.loc.gov/authorities/names/n2018183930
_0http://viaf.org/viaf/17152682496223311016
710 2 _aSpringerLink (Online service)
_0http://id.loc.gov/authorities/names/no2005046756
_0http://viaf.org/viaf/148105729
_9106996
776 0 8 _iEdición impresa:
_z9783319618715
776 0 8 _iEdición impresa:
_z9783319618739
776 0 8 _iEdición impresa:
_z9783319871820
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-61872-2
_zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942 _2lcc
_cLE
998 _db